FDA grants breakthrough therapy designation to Ifinatamab Deruxtecan for lung cancer patients
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Phase 1 dosing is expected to finish by the end of 2025
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Subscribe To Our Newsletter & Stay Updated